<unk>  is a receptor tyrosine kinase inhibitor and is used in the treatment of canine mast cell tumor also called mastocytoma. Together with masitinib (Kinavet (US)/Masivet (EU/ROW) by AB Science),<unk>  is the only dog-specific anti-cancer drug approved by the U.S. Food and Drug Administration. It is marketed as Palladia as its phosphate salt,<unk>  phosphate (INN) by Pfizer. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies.<unk>  is likely to act mostly through inhibition of the kit tyrosine kinase, though it may also have an anti-angiogenic effect.
Toceranib
Semaxanib
Enasidenib
Cediranib
Gilteritinib
Erdafitinib
Brigatinib
Lorlatinib